Minerva

Minerva

BMJ 2008; 336 doi: https://doi.org/10.1136/bmj.a442 (Published 26 June 2008) Cite this as: BMJ 2008;336:1512
  1. Caroline Angit, specialist registrar,
  2. Loma Gardner, specialist registrar,
  3. Ian Coulson, consultant dermatologist
  1. 1department of dermatology, Burnley General Hospital, Burnley BB10 2PQ
  1. carolineangit{at}hotmail.co.uk

    A 40 year old woman with rheumatoid arthritis had received etanercept, a tumour necrosis factor (TNF) antagonist, …

    View Full Text

    Sign in

    Log in through your institution

    Subscribe